An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database

References

• Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–546. doi:10.7326/M19-1208
   PubMed Web of Science ®Google Scholar
• FranceCoag. National statistics - demographic: haemophilia A 2023 [cited 2023 Jan 20]. Available from: https://francecoag.org/SiteWebPublic/public/stats/stats_page.jsp?stat2 = on.
   Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. Wfh guidelines for the management of hemophilia. 3rd ed. Haemophilia. 2020;26(Suppl. 6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–1939. doi:10.1111/jth.12672
   PubMed Web of Science ®Google Scholar
• Ministère de la santé et de la prévention - base de données publique des médicaments. Factane - Summary of Product Characteristics [cited 2023 Jan 24]. Available from: https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid = 66716833&typedoc = R
   Google Scholar
• European Medicines Agency. Advate - summary of product characteristics [cited 2023 Jan 24]. Available from: https://www.ema.europa.eu/en/documents/product-information/advate-epar-product-information_en.pdf.
   Google Scholar
• European Medicines Agency. Elocta - summary of product characteristics. 2019 [cited 2022 March]. Available from: https://www.ema.europa.eu/en/documents/product-information/elocta-epar-product-information_en.pdf.
   Google Scholar
• Haute Authorité de Santé. Adynovi (rurioctocog alfa pegol). Commission de le Transparence Avis, 10 avril 2019 [cited 2023 June 20]. Available from: https://www.has-sante.fr/jcms/c_2965047/en/adynovi-rurioctocog-alfa-pegol.
   Google Scholar
• Haute Autorité de Santé. Jivi (damoctacog alfa pegol). Commission de la Transparence Avis, 5 juin 2019 [cited 2023 June 20]. Available from: https://www.has-sante.fr/upload/docs/evamed/CT-17559_JIVI_PIC_INS_Avis3_CT17559.pdf.
   Google Scholar
• Haute Autorité de Santé. Esperoct (turoctocog alfa pegol). Commission de la Transparence Avis, 10 mars 2021 [cited 2023 June 20]. Available from: https://www.has-sante.fr/jcms/p_3242180/en/esperoct-turoctocog-alfa-pegol.
   Google Scholar
• Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–962. doi:10.1002/pds.4233
   PubMed Web of Science ®Google Scholar
• Horvais V, Wargny M, Repesse Y, et al. rFVIII-Fc in severe haemophilia A: the incentive switch in case of high risk of joint bleedings. Eur J Clin Invest. 2022;52(10):e13824. doi:10.1111/eci.13824
   PubMed Web of Science ®Google Scholar
• Giraud R, Delmotte N, Gensollen S, et al. Recombinant factor VIII Fc fusion protein (rFVIIIFc) in real life: one-year clinical and economic outcomes. Drugs Real World Outcomes. 2021;8(4):527–535. doi:10.1007/s40801-021-00259-2
   PubMedGoogle Scholar
• Nummi V, Lehtinen AE, Iorio A, et al. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: comparison of factor product use, bleed rates and pharmacokinetics. Haemophilia. 2022;28(6):e237–e244. doi:10.1111/hae.14649
   PubMed Web of Science ®Google Scholar
• Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the systeme national d'information interregimes de l'Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S149–S167. doi:10.1016/j.respe.2017.05.004
   PubMedGoogle Scholar
• Laurendeau C, Goudemand J, Trossaert M, et al. Costs and management of patients with hemophilia A in France: the Hemraude study. Eur J Health Econ. 2022;23(1):23–32. doi:10.1007/s10198-021-01339-4
   PubMed Web of Science ®Google Scholar
• Dispositif FranceCoag. Cohorte française des patients vivant avec une maladie hemorragique constitutionnelle. Données descriptives au 31 décembre 2021 2022. Available from: https://francecoag.org/SiteWebPublic/pdfs/rapports_annuels_publics/2021_Rapport_annuel_FC.pdf.
   Google Scholar
• Berntorp E, Dolan G, Hay C, et al. European retrospective study of real-life haemophilia treatment. Haemophilia. 2017;23(1):105–114. doi:10.1111/hae.13111
   PubMed Web of Science ®Google Scholar
• Réseau FranceCoag. Cohorte française des patients atteints de maladies hémorragiques par déficits héréditaires en protéines de la coagulation - Données descriptives 2005 2005 [cited 2023 Jan 24]. Available from: https://www.vie-publique.fr/sites/default/files/rapport/pdf/064000522.pdf.
   Google Scholar
• Holmström M, Olsson E, Astermark J, et al. Real-world prophylactic usage of recombinant factor VIII Fc in Sweden: a report from the Swedish national registry for bleeding disorders. Haemophilia. 2021;27(4):e554–e558. doi:10.1111/hae.14316
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Garagiola I, Boscarino M, et al. Real-life experience in switching to new extended half-life products at European haemophilia centres. Haemophilia. 2019;25(6):946–952. doi:10.1111/hae.13834
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Kovaltry - summary of product characteristics [cited 2023 Jan 24]. Available from: https://www.ema.europa.eu/en/documents/product-information/kovaltry-epar-product-information_en.pdf.
   Google Scholar
• European Medicines Agency. Helixate NextGen - summary of product characteristics [cited 2023 Jan 24]. Available from: https://www.ema.europa.eu/en/documents/product-information/helixate-nexgen-epar-product-information_en.pdf.
   Google Scholar
• van der Sluijs M, Huyghe N, Wood C, et al. A survey of physicians’ treatment switching practice in people on long-term prophylaxis for hemophilia in five European countries. Curr Med Res Opin. 2022;38(1):65–73. doi:10.1080/03007995.2021.1991901
   PubMed Web of Science ®Google Scholar
• Tagliaferri A, Matichecchia A, Rivolta GF, et al. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience. Blood Transfus. 2020;18(5):374–385.
   PubMed Web of Science ®Google Scholar
• Ay C, Feistritzer C, Rettl J, et al. Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria. Sci Rep. 2021;11(1):12967. doi:10.1038/s41598-021-92245-5
   PubMed Web of Science ®Google Scholar
• Goldmann G, Marquardt N, Horneff S, et al. Real-world clinical experience of extended half-life recombinant factor VIII Fc fusion protein (rFVIIIFc) in comparison to conventional factor products in patients with severe hemophilia A. J Curr Med Res Opin. 2021;4(05):950–960. doi:10.15520/jcmro.v4i05.422
   Google Scholar
• Oldenburg J, Hay C, Peyvandi F, et al. Recombinant factor VIII Fc showed better prophylactic effectiveness compared to standard half-life factor VIII in haemophilia A –results from A-SURE, a 24-month prospective, non-interventional study. Res Pract Thromb Haemost. 2022;6(S1):79–80.
   Google Scholar
• Chhabra A, Spurden D, Fogarty PF, et al. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagul Fibrinolysis. 2020;31(3):186–192. doi:10.1097/MBC.0000000000000885
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study identifier NCT04293523. A 48-month study to evaluate long-term effectiveness of elocta on joint health (A-MORE) [cited 2023 May 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT04293523.
   Google Scholar
• ClinicalTrials.gov. Study identifier NCT03055611. A study to evaluate real-world usage and effectiveness of Elocta and Alprolix in patients with Haemophilia A or B (PREVENT) [cited 2023 May 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT03055611.
   Google Scholar